FOLH1 and prostate adenocarcinoma: <h4>Purpose</h4>To predict metastasis-free survival (MFS) for patients with prostate adenocarcinoma (PCa) treated with androgen deprivation therapy (ADT) and external radiotherapy using clinical factors and radiomics extracted from primary tumor and node volumes in pre-treatment PSMA PET/CT scans.<h4>Materials/methods</h4>Our cohort includes 134 PCa patients (nodal involvement in 28 patients).